Enaiblers AB acquires AI-based Digital Pathology Technology from Johnson & Johnson

We are thrilled to announce the launch of Enaiblers, a social enterprise, with a vision to improve global health equity by empowering communities with affordable AI-based diagnostics.

Enaiblers’ founders Peter Ward and Peter Dahlberg have been involved in the development of the AI-based digital pathology platform since its inception in 2018. “We are committed to bring this enabling technology to market and make it accessible to those most in need” said co-founder Peter Ward.

Following important milestones like the WHO 2030 roadmap Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021−2030 and the Kigali declaration, the announcement of this divestiture to Enaiblers also highlights the commitment from Johnson & Johnson in tackling Neglected Tropical Diseases.

“We are excited to announce the divestiture of this transformational technology to Enaiblers” said Lieven Stuyver, Senior Scientific Director, Janssen Research & Development, LLC. “Enaiblers has a clear vision for the future of this technology and we believe that Enaiblers is the best place for it to reach its full potential.”

The technology is an affordable AI-based digital pathology (AIDP) system developed for settings with limited infrastructure and for ease of adoption. The development of the system has involved many collaborators, most recently through the AI4NTD consortium (www.ai4ntd.org).

With funding from Johnson & Johnson Foundation, Enaiblers are currently planning field studies in Uganda and Ethiopia together with collaborators from Vector Control Division, Ministry of Health Uganda, Jimma University and Ghent University to further validate the system. “We look forward to working together with all the committed people in the NTD space and to contribute in reaching the elimination targets of the WHO 2030 roadmap for Neglected Tropical Diseases.” says Enaiblers co-founder Peter Dahlberg.